

Original article

Hydration status and blood pressure variability in primary hypertensive patients

Oguzhan Sıtkı Dizdar^{a,*}, Ali Yeşiltepe^b, Engin Dondurmacı^c, Eyup Ozkan^c, Ali Koç^d, Ali Ihsan Gunal^e

^a Department of Internal Medicine and Clinical Nutrition, Kayseri City Training and Research Hospital, Kayseri, Turkey

^b Department of Internal Medicine, Kayseri City Training and Research Hospital, Kayseri, Turkey

^c Department of Cardiology, Kayseri City Training and Research Hospital, Kayseri, Turkey

^d Department of Radiology, Kayseri Training and Research Hospital, Kayseri, Turkey

^e Department of Internal Medicine Division of Nephrology, Kayseri City Training and Research Hospital, Kayseri, Turkey

ARTICLE INFO

Article history:

Received 2 July 2019

Accepted 7 February 2020

Available online 11 June 2020

Keywords:

Blood pressure variability

Fluid status

Cardiac functions

Endothelium

Hypertension

ABSTRACT

Background: Increased blood pressure variability (BPV) is associated with higher cardiovascular risk. The association between BPV and fluid status in hypertensive patients has not been investigated so far. The aim of the present study was to determine the contribution of fluid balance to BPV and impact on endothelial and cardiac functions among primary hypertensive patients.

Methods: This is a prospective interventional study conducted in primary hypertensive patients with one-year follow-up. Volume status measurements by a body composition monitor, ambulatory blood pressure (BP) monitoring, echocardiographic and carotid intima-media thickness (CIMT) measurements were performed at enrollment and at twelfth. Patients in one of the two groups were kept negative hydrated during trial with diuretic treatment. Patients in other group were positively hydrated (hypervolemic) at enrollment, antihypertensive drugs other than diuretics (vasodilator agents) were added or intensified according to the BP monitoring. Average real variability (ARV) index was used for establishing the prognostic significance of BPV.

Results: The study population consisted of 50 patients with a mean age of 54.5 ± 8.8 years. At the end of one-year follow-up, patients in negative hydrated group were found to have significantly lower BP, CIMT, left ventricle mass index (LVMI) and systolic and diastolic ARV. More weight gain and higher systolic BP were major risk factors of high systolic ARV. Patients who have improvement in CIMT and LVMI were considered as target organ damage (TOD) recovery present. In negatively hydrated group, TOD significantly reduced during trial. In patients who have TOD recovery, BPV significantly more reduced like systolic and diastolic BP. Significant risk factors associated with the presence of TOD were 24 h systolic BP and daytime and night time diastolic ARV and night time diastolic BP.

* Corresponding author.

E-mail address: osdizdar@gmail.com (O.S. Dizdar).

<http://dx.doi.org/110.1016/j.nefro.2020.02.002>

2013-2514/© 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Conclusion: Addition of diuretic to established treatment or intensified diuretic treatment and keeping patients in negative hydration status resulted in reduction in BPV at twelfth month of follow-up. More weight gain and higher systolic BP are major risk factors of high systolic ARV, but not hypervolemia. BPV, especially diastolic ARV, was significantly associated with TOD.

© 2020 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Estado de hidratación y variabilidad en la presión arterial en pacientes con hipertensión primaria

RESUMEN

Palabras clave:

Variabilidad en la presión arterial

Estado hidroelectrolítico

Funciones cardíacas

Endotelio

Hipertensión

Antecedentes: El aumento en la variabilidad en la presión arterial (VPA) se asocia con un mayor riesgo cardiovascular. Hasta el momento no se ha investigado la asociación entre la VPA y el estado hidroelectrolítico en pacientes hipertensos. El objetivo del presente estudio fue determinar la contribución del equilibrio hidroelectrolítico a la VPA y el impacto en las funciones endoteliales y cardíacas entre los pacientes con hipertensión primaria.

Métodos: Se trata de un estudio intervencionista prospectivo realizado en pacientes con hipertensión primaria con seguimiento de un año. Se llevaron a cabo mediciones del estado volumétrico mediante un monitor de composición corporal, monitorización de presión arterial (PA) ambulatoria, mediciones ecocardiográficas y del grosor de la íntima-media de la carótida (GIMC) en la inclusión y en el duodécimo mes. En los pacientes de uno de los 2 grupos se mantuvo hidratación negativa durante el ensayo con tratamiento diurético. Los pacientes de otro grupo presentaban hidratación positiva (hipervolemia) en la inclusión, y se añadieron o se intensificaron los fármacos antihipertensivos distintos de los diuréticos (vasodilatadores) en función de la monitorización de la PA. Se utilizó el índice de variabilidad real promedio (VRP) para establecer la significación pronóstica de la VPA.

Resultados: La población del estudio consistió en 50 pacientes con una media de edad de $54,5 \pm 8,8$ años. Al final del seguimiento, al cabo de un año, los pacientes del grupo con hidratación negativa presentaron una PA, un GIMC, un índice de masa del ventrículo izquierdo (IMVI) y una VRP sistólica y diastólica significativamente menores. El mayor aumento de peso y una PA sistólica superior fueron factores de riesgo importantes de la VRP sistólica alta. Los pacientes con mejoras en el GIMC y el IMVI se consideraron pacientes con recuperación del daño de órganos diana (DOD). En el grupo con hidratación negativa, el DOD se redujo significativamente durante el ensayo. En los pacientes con recuperación del DOD, la VPA se redujo significativamente en mayor medida, al igual que la PA sistólica y diastólica. Los factores de riesgo significativos asociados con la presencia de DOD fueron la PA sistólica de 24 h, la VPA diastólica diurna y nocturna y la PA diastólica nocturna.

Conclusión: La adición de diuréticos al tratamiento establecido o la intensificación del tratamiento diurético y el mantenimiento de los pacientes en estado de hidratación negativa provocó la reducción de la VPA en el duodécimo mes de seguimiento. El mayor aumento de peso y una PA sistólica superior son factores de riesgo importantes de VRP sistólica alta, pero no así la hipervolemia. La VPA, en especial la VPA diastólica se asoció de forma significativa al DOD.

© 2020 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Hypertension causes development of organ damage over time and it is associated with an increased risk of cardiovascular and cerebrovascular diseases, and renal failure. It is well known that fluid retention plays a role in the pathogenesis of primary hypertension. Furthermore, fluid retention is known

to adversely affect the cardiovascular system, independent of the blood pressure level.¹

Blood pressure (BP) fluctuations are a result of the interplay between external environmental stimuli, vascular environment and biological autonomic circulatory regulation.² Spontaneous variation in blood pressure based on 24-h ambulatory blood pressure monitoring (ABPM) is referred to as blood pressure variability (BPV)^{3,4} and fluctuation during a 24-h

period is referred to as short-term BPV. Average real variability (ARV) is an index that also averages the absolute differences of consecutive measurements.^{5,6} The ARV index is sensitive to the individual BP measurement order and the relatively low sampling frequency of ABPM and is not affected by the mean BP level.^{5,7}

Increased short-term BPV predicts organ damage^{8,9} and is associated with an increased risk of cardiovascular events.¹⁰⁻¹⁶ The mechanism of this relationship is not clear. Ozkayar et al. found that primary hypertensive patients with high dietary salt intake had high BPV¹⁷ and this relationship was independent of the blood pressure level. This conclusion suggests that hypervolemia may also be related to BPV. However, the association between BPV assessed by ABPM and fluid status measured by bioimpedance spectroscopy method in hypertensive patients has not been investigated so far and the relationship between them is not clearly known. For these reasons, in the performed study, we aimed (1) to establish the impact of hydration status on BPV; (2) to investigate potential effect of diuretics on BPV; (3) to examine the potential role of BPV in endothelial and cardiac functions among primary hypertensive patients. It is the first study to evaluate cardiac and endothelial functions along with volume status and BPV among primary hypertensives with no kidney failure. Clarifying the relation of body fluid and BPV in primary hypertensive population could offer specific therapeutic approaches with remarkable impact on this affection.

Methods

Study design and participants

This is a prospective study in patients admitted to the nephrology, internal medicine, and cardiology clinics of a tertiary research hospital between May and August 2015, who were on follow-up with primary hypertension diagnosis. Patients were followed until August 2016. All hypertensive patients aged over 18 years included in the study regardless of gender. Patients with glomerular filtration rate (GFR) below 60 ml/min/1.73 m², pregnancy, significant psychiatric and mental problems, heart failure, nephrotic syndrome, chronic inflammatory diseases, diabetes and malignancies; patients who did not give consent; who are bedridden or are in need of care; and those with low performance scores were excluded from the study. Patients who had clinical clues suggesting the possible presence of secondary hypertension were also excluded from the study. We chose to use a highly standard method such as ambulatory blood pressure measurement to analysis hypertension. Ambulatory blood pressure monitoring provides an accurate profile of blood pressure fluctuations over a 24-h period and control for the “white coat effect”, and may show the paroxysmal rise in blood pressure associated with pheochromocytoma.

Body mass index (BMI) was calculated as weight (kg)/height (m²). This study was performed in accordance with the Helsinki Declaration and approved by local ethics committee. We obtained written informed consent from all patients.

Follow-up of patients and antihypertensive treatment strategy

At enrollment, volume status measurements were performed by a body composition monitor (BCM), and then, the patients were put on ambulatory blood pressure monitoring for 24 h. Then, echocardiographic assessments were completed in the cardiology clinic; and carotid intima-media thickness (CIMT) measurements were done by a radiologist. Patients who had negative overhydration (OH) value (OH value ≤ 0) (normovolemic) at enrollment received diuretic treatment as an antihypertensive drug during trial. These patients were either receiving diuretic or diuretic newly added to their antihypertensive treatments and dose of diuretics were increased or decreased according to bioimpedance spectroscopy measurements. Therefore, we tried to keep the patients negative hydrated during trial in this group. In patients who had positive OH value (OH value > 0) (hypervolemic) at enrollment, antihypertensive drugs other than diuretics (vasodilator agents) were added or intensified according to the blood pressure monitoring. If these patients had already received diuretics before study enrollment, diuretics did not cease. All subjects were followed for one year and they returned at least monthly for additional blood pressure measurements and medication (diuretic and other antihypertensives) titration during this period. Thus, patients with a normovolemic status at study entry remained normovolemic during the 1-year follow up period, while those with a hypervolemic status remained hypervolemic during the same period. Subjects were excluded from participation if they were unable to return monthly during the trial or if the physician identified non-compliance with medications.

Ambulatory blood pressure monitoring, echocardiographic measurements and CIMT measurements were repeated at twelfth month after enrollment. Fluid status of patients was measured four times during the study period; at enrollment, fourth, eighth, and twelfth month after enrollment. While analyzing patient data at the end of the study, we divided patients into two groups according to their OH values in four different bioimpedance spectroscopy measurements during study period. The negative hydrated group consisted of patients with two or more negative OH values and the positive hydrated group consisted of patients with a positive OH value in the three or four measurements.

Body composition monitoring

The fluid status was assessed by a bioimpedance spectroscopy method, using the BCM (BCM, Fresenius Medical Care, GmbH, Germany) and was represented by the level of OH. BCM device was connected with four disposable electrodes placed on upper and lower limbs of the patients. Bioimpedance analysis was performed in a standard manner and measurements were performed in supine position by a trained medical doctor. Gender, height (cm), body weight (kg), and arterial blood pressure (systolic and diastolic mmHg) information were entered for each patient. Using the non-invasive bioimpedance method, hydration status, urea distribution volume, total body fluid, intracellular fluid, intercellular fluid, lean tissue index, fatty tissue index, and body cell mass were measured. BCM has

been validated extensively against all available gold standard methods in the general populations.¹⁸ Fluid status of patients was measured four times during the study period at enrollment, fourth, eighth, and twelfth month after enrollment. Patients who had the level of OH \leq 0L were considered negatively hydrated (normovolemic) and patients who had the level of OH $>$ 0L were considered positively hydrated (hypervolemic).

Ambulatory blood pressure monitoring

The 24-hour blood pressure monitoring of the patients was performed with Mobil-O-Graph NG and Mobil-O-Graph PWA (I.E. M. GmbH, Stolberg, Germany) ambulatory blood pressure devices. The device was attached to the patient's less dominant arm. Measurements were performed at intervals of 15–60 min throughout the whole monitoring period. The device was programmed to record the BP of the patient with 30–60 min intervals while asleep and with 15–30 min intervals while awake. When the readings exceeded at least 70% of the total readings programmed for the testing period, the recording was considered valid and satisfactory. The patients who participated in the study were advised to continue their usual daily activities, to refrain from excessive emotional and physical stress, and to be still and holding their arms at the heart-level while measurements were made. Systolic readings values greater than 260 mmHg or lower than 70 mmHg as well as diastolic readings greater than 150 mmHg or lower than 40 mmHg were discarded.

Blood pressure variability

To improve the predictive power of 24-h BPV, Mena et al proposed the ARV index.⁵ This method focuses on changes occurring over short time intervals and, thus, corrects some of the limitations of SD, which only reflects the dispersion of BP measurements around the mean. ARV index was a more reliable index for establishing the prognostic significance of BPV.⁵

ARV index is calculated using the following formula:

$$ARV = \frac{1}{N-1} \sum_{k+1}^{N-1} BP_{k+1} - BP_k$$

where N denotes the number of valid blood pressure (BP) measurements in the ABPM data corresponding to a given subject and k is the order of measurements.

Target organ damage

Echocardiographic measurements were recorded and analysed offline by experienced investigators who were unaware of the clinical data of the participants. Left ventricular mass index (LVMI) was determined from transthoracic 2-dimensional targeted M-mode echocardiography with the participants in the partial left decubitus position.

LVMI was calculated using Devereux formula.¹⁹

$$LVMI = \frac{0.8(1.04((LVEDd + IVT + PWT) 3 - LVEDd3)) + 0.6}{\text{body surface area}}$$

(Body surface area = 0.007184 * Height (cm)^{0.725} * Weight (kg)^{0.425})

Values below 115 g/m² among males and 95 g/m² among women were considered normal, while values above were considered as hypertrophic.

A single-experienced radiologist made the CIMT measurements with Toshiba Aplio 500 (Toshiba Co. Ltd. Tokyo, Japan) ultrasound device, at B mode 7.5–12 MHz using surface probes. For ultrasound analysis, intima-media thickness was measured by utilizing the characteristic echogenicity of the lumen-intima and media-adventitia surfaces. Patients with CIMT of 0.9 mm or more were considered at cardiovascular risk, and those with less thickness were evaluated as normal.

Target organ damage (TOD) was defined as LVMI values above 115 g/m² among males and 95 g/m² among women and CIMT of 0.9 mm or more.

Statistical analysis

The data were analyzed using IBM SPSS Statistics 22.0 (IBM Corp., Armonk, New York, USA) statistical software. Descriptive statistics provided are unit counts (n), percentage (%), median (range) and mean \pm standard deviation. Normality of the distribution of numerical variables was evaluated with Shapiro–Wilk normality test and Q–Q graphs. Between-group comparisons were made using the independent samples t-test for variables with normal distribution or the Mann–Whitney U-test for non-normal distribution. Relationships between categorical variables in two independent groups were investigated using the chi-square test or Fisher's exact test method. When the variables were considered dependent, the Mc Nemar test was used. Logistic regression analysis was used to determine the relative risks of developing high systolic ARV. Only the variables with a statistically significant association in the simple logistic regression model were included in the multiple logistic regression model. Odds ratios (OR) and 95% confidence intervals (CI) were determined. Generalize Linear Mixed Model for repeated measure with a binary logistic function was used to determine the factors affecting TOD at follow-up. Level of statistical significance was set as $p < 0.05$.

Results

The study population consisted of 50 patients with a mean age of 54.5 \pm 8.8 years. We divided all patients into two groups according to their volume status throughout the one year. The first group consisted of 31 patients with two or more negative OH values (\leq 0 OH value) in four different bioimpedance spectroscopy measurements. The second group consisted of 19 patients with a positive OH value (0 $>$ OH value) in the three or four measurements. Thus, the patients in the first group consisted of patients continuing in negative hydrated status and the patients in the second group consisted of patients who were positive hydrated throughout one-year follow-up. Twenty-six patients in negatively hydrated group received diuretic, 12 (44.4%) of them received 12.5 mg hydrochlorothiazide, and 14 (54%) of them received 25 mg hydrochlorothiazide. Only 1 patient received diuretic (25 mg hydrochlorothiazide) in positively hydrated group. The baseline characteristics of the

Table 1 – Comparisons of patients according to hydration status at enrollment.

Variable	Positive hydrated group (OH > 0) n = 19	Negative hydrated group (OH ≤ 0) n = 31	p
Gender, M/F	13(68.4)/6(31.6)	8(25.8)/23(74.2)	0.007
Age	54.8 ± 11.2	54.3 ± 7.2	0.832
Weight (kg)	85.5 ± 17.4	81.3 ± 12.6	0.323
BMI	29.7 ± 4.9	31.4 ± 5.6	0.287
BUN	15.7 ± 3.3	15.4 ± 3.7	0.800
Creatinin	0.9 ± 0.2	0.8 ± 0.1	0.035
Diuretic usage			
Yes	1 (5.3)	26 (83.9)	<0.001
No	18 (94.7)	5 (16.1)	
Mean systolic BP, (mmHg)	130.5 ± 17	126.5 ± 17.2	0.431
Mean diastolic BP, (mmHg)	82.1 ± 12.5	79.9 ± 10.8	0.516
Systolic ARV	15.6 ± 4.1	16.5 ± 4.8	0.489
Diastolic ARV	12.6 ± 3.3	12.6 ± 4.7	0.995

Data are expressed as the mean ± SD, or noun (percentage). OH: Overhydration value, M: Male, F: Female, BMI: Body mass index, BUN: Blood urea nitrogen, BP: Blood pressure.

patients in both groups are presented in [Table 1](#). The patients in both groups were similar with regard to age, BUN and BMI but male ratio was more prevalent in positive hydrated group. Diuretic usage in negative hydrated group was significantly higher than other group at enrollment. No patient died during study period. At the end of one-year follow-up, there were no significant changes with regard to weight, height and BMI between basal and twelfth month measurements in patients in both groups.

Systolic and diastolic ARV significantly decreased in both groups (positively and negatively hydrated) along with decrease in blood pressure at the end of the twelfth month. This result can be attributed to antihypertensive treatment (diuretic or vasodilator drugs) in both groups. But, systolic and diastolic ARV (24-h, daytime, nighttime) significantly more decreased in negatively hydrated group than positively hydrated group ([Table 2](#)). Similarly, at the end of one-year follow-up, patients in negative hydrated group were found to have significantly lower mean systolic (110.1 ± 14.6 and 128.4 ± 17.1; respectively) and diastolic BP (70.4 ± 7.7 and 80.3 ± 9.8; respectively) compared with baseline ($p = 0.0011$ and $p = 0.033$; respectively). More diuretics (hydrochlorothiazide) were used in the negative hydrated group to control of arterial hypertension (83.9% and 5.3%; respectively. $p < 0.001$). 55.6% of the patients receiving diuretics used 25 mg hydrochlorothiazide and the rest used 12.5 mg hydrochlorothiazide.

We investigated the effects of parameters on the development high systolic ARV. High systolic ARV was defined as higher systolic ARV levels of the third tertile (15.32) of ARV distribution. The first tertile and median of systolic ARV were 10.72 and 12.8, respectively. Logistic regression analysis was used to determine the relative risks of developing high systolic ARV at the end of the one year follow-up. Only the variables with a statistically significant association in the simple logistic regression model were included in the multiple logistic regression model. In multiple logistic regression analysis, significant risk factors associated with high systolic ARV were as follows:

more weight gain during follow-up and higher systolic blood pressure ([Table 3](#)).

In our study, target organ damage (TOD) was defined as LVMI values above 115 g/m² among males and 95 g/m² among women and CIMT of 0.9 mm or more. Patients who have improvement in both of these two parameters were considered as TOD recovery present. In patients who have TOD recovery, BPV significantly more reduced than patients with no improvement in TOD, like systolic BP and diastolic BP ([Table 4](#)). We investigated factors associated with the presence of TOD at follow-up with Generalize Linear Mixed Model for repeated measure with a binary logistic function at [Table 5](#). Significant risk factors associated with the presence of TOD at follow-up were as follows: 24 hour systolic BP and daytime and night time diastolic ARV and night time diastolic BP.

Discussion

To the best of our knowledge, this is the first study that directly investigates the effect of the volume status on short-term BPV in a group of primary hypertensive patients who do not have kidney failure. It was found that patients with negative hydration status are characterised by lower values of systolic BPV. Although we did not show the relationship between high systolic ARV and OH value in multiple logistic regression analysis, more weight gain which is an indicator of volume increase was associated with high systolic ARV. In our previous study, we showed the significance of negative hydration status with respect to blood pressure control, endothelial, and cardiac functions within same population.²⁰ Increased BPV is clearly associated with higher cardiovascular risk in the general population.^{13,21,22} Hence, we have shown the importance of negative hydration status to cardiovascular protection with different ways.

Results of Levi-Marpillat et al.'s study indicate that diuretics was associated with a lower short-term BPV compared with the other classes (angiotensin II receptor blockers, angiotensin

Table 2 – Comparisons of blood pressure and blood pressure variabilities of patients according to hydration status.

Variable	Positive hydrated group (n = 19)			Negative hydrated group (n = 31)			Δp
	Basal	Twelfth month	p	Basal	Twelfth month	p	
24 h							
SBP	134.8 ± 16.6	128.4 ± 17.1	0.010*	128.4 ± 16.3	110.1 ± 14.6	<0.001*	0.011*
DBP	85.3 ± 11.7	80.3 ± 9.8	0.012*	80.7 ± 10.1	70.4 ± 7.7	<0.001*	0.033*
Systolic ARV	15.8 ± 4	13.5 ± 2.9	0.028*	16.6 ± 4.8	12.2 ± 3.2	<0.001*	0.034*
Diastolic ARV	12.3 ± 3.4	10.8 ± 1.9	0.041*	12.7 ± 4.6	9.3 ± 2.3	<0.001*	0.041*
Daytime							
SBP	137.4 ± 16.5	130.4 ± 15.9	0.019*	132.4 ± 12.7	120.6 ± 12.4	<0.001*	0.037*
DBP	87.2 ± 12.9	83.1 ± 10.5	0.015*	85.0 ± 10.2	76.1 ± 10	<0.001*	0.030*
Systolic ARV	14.9 ± 3.2	13.1 ± 3.2	0.003*	15.5 ± 3.9	12.0 ± 3.6	<0.001*	0.021*
Diastolic ARV	11.1 ± 2.2	9.8 ± 2.0	0.004*	11.1 ± 2.7	8.0 ± 2.4	<0.001*	0.015*
Nighttime							
SBP	124.7 ± 17.1	118.5 ± 18.6	0.003*	117.7 ± 16.9	100.4 ± 16.7	<0.001*	0.018*
DBP	78.1 ± 12.3	73.8 ± 14.5	0.006*	74.2 ± 11.5	65.1 ± 9.4	<0.001*	0.045*
Systolic ARV	12.8 ± 2.7	10.8 ± 2.8	0.001*	11.4 ± 3.4	7.0 ± 2.6	<0.001*	0.012*
Diastolic ARV	9.8 ± 1.8	9.0 ± 1.6	0.007*	9.6 ± 2.4	7.2 ± 2.4	<0.001*	0.038*

ARV: Average real variability, SBP: systolic blood pressure, DBP: diastolic blood pressure, Δp : comparison of negative (twelfth month—basal) and positive (twelfth month—basal) hydrated group.
Data are expressed as the mean ± SD.
* Significant values $p < 0.05$ are shown.

Table 3 – Results of univariate and multiple logistic regression analysis for risk factors for high systolic ARV at the end of the one year follow-up.

Risk factors	High OR	Systolic ARV ^a 95% CI	p
Univariate analysis			
Age	0.986	0.916–1.060	0.698
Gender	1.917	0.535–6.872	0.318
Δ Body weight	1.327	1.020–1.727	0.035
Δ Blood urea nitrogen	1.122	0.942–1.337	0.198
Δ Creatinin	0.396	0.001–422.99	0.794
Systolic blood pressure	1.092	1.032–1.155	0.002
Diastolic blood pressure			
Δ OH value	1.615	0.596–4.373	0.346
Negative hydrated group	2.431	0.669–8.825	1.177
Diuretic usage	1.531	0.430–5.451	0.511
Δ Extacellular water	1.091	0.923–1.289	0.308
Multiple analysis			
Δ Body weight	1.384	1.008–1.900	0.044
Systolic blood pressure	1.097	1.033–1.166	0.003

^a High systolic ARV was defined as higher systolic ARV levels of the third tertile (15.32) of ARV distribution. OR, odds ratio; CI, confidence interval; Δ : Difference between follow-up.

converting enzyme inhibitors and beta blockers).²³ The X-CELLENT trial showed that diuretics, but not angiotensin II receptor blockers, lead to a decrease of 24-h BPV compared with placebo.²⁴ A meta-analysis of randomized trials concluded for a reduction of the visit-to-visit variability in systolic BP, that is, fluctuations of systolic BP over long periods of observation, with the use of non-loop diuretics.²⁵ The results of our study explain how diuretics have BPV lowering effect. We used diuretics to keep the patients negative hydrated during trial and we showed that if the patients were negative hydrated with diuretic usage, they showed better decrease in BPV. The results of our work proved that reduction in BPV due to diuretic use depends on the volume reduction. In terms of explaining

mechanism, this research may be considered preliminary as no comparable studies were found in the literature.

Several studies based on 24-h ABPM have shown that antihypertensive drugs decrease ambulatory BPV, a reduction which is proportional to the decrease in mean BP values, suggesting that the effect of antihypertensive treatment on short-term BPV may be largely dependent on the BP lowering, per se.^{26,27} But, in our study we found a collinearity between the reduction in OH value and BPV, as well as between the reduction in BP and BPV. This situation was independent from blood pressure level. Like ours, a different study showed that antihypertensive drug classes may have different effects on short-term BP variability in a daily life clinical setting, independently

Table 4 – Change in blood pressure levels and blood pressure variabilities according to recovery of target organ damage.

Variable	Basal target organ damage (+)						Δp
	Twelfth month recovery absent <i>n</i> = 22			Twelfth month recovery present <i>n</i> = 7			
	Basal	Twelfth month	<i>p</i>	Basal	Twelfth month	<i>p</i>	
24 h							
SBP	127.1 ± 16.2	118.4 ± 16.7	<0.001*	136.1 ± 20	118.1 ± 15.5	<0.001*	0.011*
DBP	83.3 ± 10.4	75.4 ± 9.1	<0.001*	86.3 ± 12.8	70.6 ± 9.4	<0.001*	0.018*
Systolic ARV	15.9 ± 4.6	12.9 ± 2.9	<0.001*	19.4 ± 4.2	14.3 ± 4.5	<0.001*	0.001*
Diastolic ARV	12.3 ± 4.1	9.9 ± 2.1	<0.001*	15.2 ± 4.6	9.8 ± 2.5	<0.001*	0.002*
Daytime							
SBP	134.6 ± 13.6	124.2 ± 14.6	<0.001*	142.4 ± 19.1	122.4 ± 21.3	<0.001*	0.013*
DBP	85.9 ± 11.1	79.3 ± 10.5	<0.001*	89.1 ± 12.2	76.2 ± 10.2	<0.001*	0.024*
Systolic ARV	14.9 ± 3.4	12.3 ± 3.3	<0.001*	17.9 ± 4.9	13.3 ± 4.7	<0.001*	0.001*
Diastolic ARV	11.0 ± 2.5	8.9 ± 2.3	<0.001*	13.1 ± 2.2	8.2 ± 2.5	<0.001*	0.001*
Night time							
SBP	121.1 ± 17.1	109.7 ± 18.4	<0.001*	125.6 ± 17.9	106.3 ± 15.9	<0.001*	0.016*
DBP	76.2 ± 11.7	68.7 ± 12	<0.001*	82.7 ± 12.8	63.1 ± 8.8	<0.001*	0.001*
Systolic ARV	11.9 ± 3.2	8.6 ± 2.9	<0.001*	13.4 ± 3.6	7.3 ± 3.4	<0.001*	0.001*
Diastolic ARV	9.6 ± 2.1	7.9 ± 2.1	<0.001*	10.0 ± 3.0	7.5 ± 3.3	<0.001*	0.024*

Target organ damage was defined as left ventricle mass index values below 115 g/m² among males and 95 g/m² among women and carotid intima media thickness of 0.9 mm or more. Patients who have improvement in both of these two parameters were considered as target organ damage recovery present. Data are expressed as the mean ± SD.

ARV: Average real variability, SBP: systolic blood pressure, DBP: diastolic blood pressure Δp : comparison of recovery absent (twelfth month–basal) and recovery present (twelfth month–basal) group.

* Significant values *p* < 0.05 are shown.

Table 5 – Factors associated with the presence of target organ damage at follow-up (Generalize Linear Mixed Model for repeated measure with a binary logistic function).

Variable	Nonadjusted		Adjusted model I		Adjusted model II	
	B (95% CI)	<i>p</i>	B (95% CI)	<i>p</i>	B (95% CI)	<i>p</i>
OH levels	0.78 (0.48–1.24)	0.281	0.68 (0.41–1.14)	0.139	1.18 (0.61–2.28)	0.614
Pozitif OH	1.44 (0.63–3.30)	0.385	1.47 (0.62–3.44)	0.377	1.30 (0.54–3.17)	0.556
24 h						
SBP	0.97 (0.95–0.99)	0.046*	0.97 (0.94–0.99)	0.020*	0.97 (0.94–0.98)	0.047*
DBP	0.96 (0.93–0.99)	0.005*	0.94 (0.90–0.98)	0.010*	0.96 (0.91–1.01)	0.053
Systolic ARV	0.96 (0.87–1.06)	0.425	0.96 (0.87–1.06)	0.391	0.96 (0.87–1.07)	0.439
Diastolic ARV	0.92 (0.81–1.04)	0.17	0.90 (0.80–1.02)	0.1	0.91 (0.81–1.04)	0.155
Daytime						
SBP	0.98 (0.95–1.01)	0.093	0.97 (0.95–1.02)	0.13	0.98 (0.95–1.01)	0.145
DBP	0.96 (0.93–0.99)	0.008*	0.95 (0.91–0.99)	0.015*	0.96 (0.92–1.01)	0.053
Systolic ARV	0.88 (0.78–0.99)	0.038*	0.90 (0.80–1.01)	0.07	0.91 (0.80–1.03)	0.118
Diastolic ARV	0.74 (0.62–0.89)	0.002*	0.76 (0.63–0.90)	0.003*	0.78 (0.65–0.93)	0.007*
Night time						
SBP	0.95 (0.92–0.98)	0.018*	0.97 (0.95–0.99)	0.035*	0.98 (0.95–1.01)	0.084
DBP	0.96 (0.92–0.99)	0.005*	0.95 (0.911–0.98)	0.009*	0.96 (0.92–0.99)	0.033*
Systolic ARV	0.95 (0.85–1.06)	0.365	0.94 (0.84–1.05)	0.281	0.98 (0.86–1.11)	0.694
Diastolic ARV	0.84 (0.70–0.97)	0.001*	0.76 (0.63–0.93)	0.007*	0.79 (0.65–0.97)	0.024*

Data are expressed as the mean ± SD.

OH: Overhydration value, ARV: Average real variability, SBP: systolic blood pressure, DBP: diastolic blood pressure. Adjusted Model I: Gender, Age, BMI, BUN (difference between follow-up), Creatinin (difference between follow-up) adjusted. Adjusted Model II: Gender, Age, BMI, BUN (difference between follow-up), Creatinin (difference between follow-up), Diuretic usage adjusted.

* Significant values *p* < 0.05 are shown.

from the effects of major confounders such as BP level, age, gender and heart rate.²³ This blood pressure independent effect may be related to relationship between the fluid status – BPV found in our study for the first time in the literature.

Trials should be aimed at exploring whether the benefits of BPV lowering by diuretics might translate into a cardiovascular risk reduction in humans. Indeed, the benefits of treatment-induced reduction in BPV have been related to a reduction in TOD in the setting of some experimental animal studies.^{28,29} Furthermore, BPV has been reported to impact on negative end-organ outcomes.³⁰ The present study is one of the studies that reveal the relationship between BPV and TOD. We found that TOD was less common in patients who had more decrease in BPV. Cross-sectional and longitudinal studies showed a positive association between BPV and cardiovascular risk in pure hypertensive patients. Leoncini et al assessed the independent influence of BPV on multiple target organ damage, including LV mass index, intima media thickness, and renal abnormalities.³¹ High BPV, measured as SD and ARV, was associated with the simultaneous presence of 2 or more signs of subclinical organ damage, regardless of several confounding variables, including BP. They reported that parameters of BPV and LV mass index gradually increased together, which is line with our findings. The association of systolic BPV with echocardiographic parameters was previously studied by Zakopoulos et al. and they demonstrated that a 0.1 mmHg/min increase in the daytime rate of systolic BPV was associated with an increment of 7.087 g in the left ventricular mass.³² Unlike these results, Massierer et al. did not show associations between BPV assessed through 24 h-ABPM with echocardiographic variables related to diastolic function, left ventricular hypertrophy and cardiac chamber diameters in hypertensive-diabetic patients.³³ However, the volume status of patients was not measured in this study. According to our results, we can claim that if hypovolemia was not established in the patients in Massierer et al.'s study, cardiac parameters could not be improved.

Xiong et al found that ARV generally had a strong relationship to intima media thickness as a sign of early atherosclerosis.³⁴ Another study found that ARV had the strongest relationship to arterial stiffness.³⁵ These results were confirmed that the relationship between ARV and arterial stiffness was independent from office BP and average 24-hour BP. In the present study, we analyzed short-term BPV and CIMT in negative and positive hydrated patients. Negative hydrated patients had better results for both BPV and TOD parameters including higher CIMT.

Limitations

The main limitations of the present study include the small number of patients involved in the study. Because of our non-randomized selection of patients, both groups are not properly comparable. The fact that our study group is a rather selected one and the exclusion of patients with diabetes or chronic kidney disease make our findings not entirely applicable to the population of hypertensive population at large or to patients seen by general practitioners. It must also be stressed that this research would not have been possible without statistical

measurement and no existing ABPM devices incorporate automatic quantification of ARV or other novel BPV indexes.

Conclusions

In primary hypertensive patients, we have demonstrated that addition of diuretic to established treatment or intensified diuretic treatment and keeping patients in negative hydration status resulted in more reduction in BPV along with reduced blood pressure at twelfth month of follow-up. More weight gain and higher systolic blood pressure are major risk factors of high systolic ARV, but not hypervolemia. In patients who have TOD recovery, BPV significantly more reduced than patients with no improvement in TOD, like systolic BP and diastolic BP. Potential effect of diuretics on BPV could be the guide to an optimal antihypertensive treatment in higher risk patients. Further investigation is required to define potential beneficial effects of negative hydration status, to identify treatments that reduce BPV and to clarify whether those therapeutic interventions provide additional prognostic benefit, independent of a reduction in mean BP.

Funding

The authors report no specific funding in relation to this research.

Conflict of interest

The authors declare no conflicts of interests.

REFERENCES

1. Gunal AI, Karaca I, Aygen B, Yavuzkir M, Dogukan A, Celiker H. Strict fluid volume control and left ventricular hypertrophy in hypertensive patients on chronic haemodialysis: a cross-sectional study. *J Int Med Res.* 2004;32:70–7.
2. Jafar TH, Ebrahim SB. Variations in levels of blood pressure: of prognostic value or not? *Am J Kidney Dis.* 2008;52:638–41.
3. Lewis O, Stephen Hales and the measurement of blood pressure. *J Hum Hypertens.* 1994;8:865–71.
4. Parati G, Ochoa JE, Lombardi C, Salvi P, Bilo G. Assessment and interpretation of blood pressure variability in a clinical setting. *Blood Press.* 2013;22:345–54.
5. Mena L, Pintos S, Queipo NV, Aizpurua JA, Maestre G, Sulbaran T. A reliable index for the prognostic significance of blood pressure variability. *J Hypertens.* 2005;23:505–11.
6. Parati G, Saul JP, Di Rienzo M, Mancia G. Spectral analysis of blood pressure and heart rate variability in evaluating cardiovascular regulation. A critical appraisal. *Hypertension.* 1995;25:1276–86.
7. Pierdomenico SD, Di Nicola M, Esposito AL, Di Mascio R, Ballone E, Lapenna D, et al. Prognostic value of different indices of blood pressure variability in hypertensive patients. *Am J Hypertens.* 2009;22:842–7.
8. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target-organ damage in hypertension. *J Hypertens.* 1987;5:939–48.

9. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24-hour blood pressure variability. *J Hypertens.* 1993;11:1133-7.
10. Mancia G, Parati G, Hennig M, Flatau B, Omboni S, Glavina F, et al. Relation between blood pressure variability and carotid artery damage in hypertension: baseline data from the European Lacidipine Study on Atherosclerosis (ELSA). *J Hypertens.* 2001;19:1981-9.
11. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. *Hypertension.* 2000;36:901-6.
12. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. *Circulation.* 2000;102:1536-41.
13. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW, et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. *J Hypertens.* 2003;21:2251-7.
14. Ozawa M, Tamura K, Okano Y, Matsushita K, Ikeya Y, Masuda S, et al. Identification of an increased short-term blood pressure variability on ambulatory blood pressure monitoring as a coronary risk factor in diabetic hypertensives. *Clin Exp Hypertens.* 2009;31:259-70.
15. Palatini P, Penzo M, Racioppa A, Zugno E, Guzzardi G, Anaclerio M, et al. Clinical relevance of nighttime blood pressure and of daytime blood pressure variability. *Arch Intern Med.* 1992;152:1855-60.
16. Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. *J Hypertens.* 2007;25:1087-94.
17. Ozkayar N, Dede F, Ates I, Akyel F, Yildirim T, Altunc B. The relationship between dietary salt intake and ambulatory blood pressure variability in non-diabetic hypertensive patients. *Nefrologia.* 2016;36:694-700.
18. Wabel P, Chamney P, Moissl U, Jirka T. Importance of wholebody bioimpedance spectroscopy for the management of fluid balance. *Blood Purif.* 2009;27:75-80.
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. *Am J Cardiol.* 1986;57:450-8.
20. Yeşiltepe A, Dizdar OS, Gorkem H, Dondurmacı E, Ozkan E, Koç A, et al. Maintenance of negative fluid balance can improve endothelial and cardiac functions in primary hypertensive patients. *Clin Exp Hypertens.* 2017;36:579-86.
21. Hansen TW, Thijs L, Li Y, Boggia J, Kikuya M, Bjorklund-Bodegard K, et al. Prognostic value of reading-to-reading blood pressure variability over 24 h in 8938 subjects from 11 populations. *Hypertension.* 2010;55:1049-57.
22. Johansson JK, Niiranen TJ, Puukka PJ, Jula AM. Prognostic value of the variability in home-measured blood pressure and heart rate: the Finn-Home Study. *Hypertension.* 2012;59:212-8.
23. Levi-Marpillat N, Macquin-Mavier I, Tropeano AI, Parati G, Maison P. Antihypertensive drug classes have different effects on short-term blood pressure variability in essential hypertension. *Hypertens Res.* 2014;37:585-90.
24. Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. *Hypertension.* 2011;58:155-60.
25. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. *Lancet.* 2010;375:906-15.
26. Mancia G, Omboni S, Parati G, Ravogli A, Villani A, Zanchetti A. Lack of placebo effect on ambulatory blood pressure. *Am J Hypertens.* 1995;8:311-5.
27. Parati G, Ochoa JE, Lombardi C, Bilo G. Blood pressure variability: assessment, predictive value, and potential as a therapeutic target. *Curr Hypertens Rep.* 2015;17:537.
28. Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hypertensive rats. *J Hypertens.* 2005;23:193-201.
29. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. *J Hypertens.* 2003;21:1961-7.
30. Gavish B, Ben-Dov IZ, Kark JD, Mekler J, Bursztyn M. The association of a simple blood pressure-independent parameter derived from ambulatory blood pressure variability with short-term mortality. *Hypertens Res.* 2009;32:488-95.
31. Leoncini G, Viazzi F, Storace G, Deferrari G, Pontremoli R. Blood pressure variability and multiple organ damage in primary hypertension. *J Hum Hypertens.* 2013;27:663-70.
32. Zakopoulos NA, Tsivgoulis G, Barlas G, Spengos K, Manios E, Ikonomidis L, et al. Impact of the time rate of blood pressure variation on left ventricular mass. *J Hypertens.* 2006;24:2071-7.
33. Massier D, Leiria LF, Severo MD, Ledur PDS, Becker AD, Aguiar FM, et al. Blood pressure variability and its association with echocardiographic parameters in hypertensive diabetic patients. *BMC Cardiovasc Disord.* 2016;16:4.
34. Xiong H, Wu D, Tian X, Lin WH, Li C, Zhang H, et al. The relationship between the 24 h blood pressure variability and carotid intima-media thickness: a compared study. *Comput Math Methods Med.* 2014;2014:1-9.
35. Schillaci G, Bilo G, Pucci G, Laurent S, Macquin-Mavier I, Boutouyrie P, et al. Relationship between short-term blood pressure variability and large-artery stiffness in human hypertension findings from 2 large databases. *Hypertension.* 2012;60:369-77.